AnergiX.RA Corixa

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation.
• Current RA treatments often have significant side effects.
• There is a need for targeted therapies that address the underlying autoimmune response.

Purpose of the Study:

• To develop a novel therapeutic agent for rheumatoid arthritis (RA).
• To investigate the efficacy of AnergiX.RA in inducing apoptosis of autoreactive T-cells.
• To evaluate the potential of targeting human cartilage glycoprotein HCgp39 in RA treatment.

Main Methods:

• AnergiX.RA is a complex of solubilized HLA DRB1-0401(a) and a specific peptide from human cartilage glycoprotein HCgp39.
• Phase I/II clinical trials were conducted as a randomized, blinded, placebo-controlled dose-escalation study.
• The mechanism involves engagement of T-cell receptors with AnergiX.RA to induce apoptosis in autoreactive T-cells.

Main Results:

• Preclinical studies identified HCgp39 as a target protein recognized by T-cells from RA patients.
• HCgp39 demonstrated potential in blocking arthritis in a mouse model.
• Engagement of T-cell receptors with AnergiX.RA was shown to induce apoptosis in autoreactive T-cells.

Conclusions:

• AnergiX.RA, utilizing Anergen's AnergiX technology, represents a potential targeted therapy for RA.
• The mechanism of action involves inducing apoptosis in autoreactive T-cells, thereby addressing the autoimmune basis of RA.
• Further clinical trials are expected to confirm the safety and efficacy of AnergiX.RA for rheumatoid arthritis treatment.